Browsing by Author "Bicmen, C"

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Molecular identification and characterization of rifampicin-resistant Mycobacterium tuberculosis isolates by line probe assay
    Bicmen, C; Gunduz, AT; Coskun, M; Senol, G; Ozkutuk, N; Cirak, AK; Ozacar, R
    Aim: Early identification and characterization of rifampicin-resistant (R-r) Mycobacterium tuberculosis isolates recovered from the samples of tuberculosis (TB) patients in the Aegean (West Anatolian) Region was intended. Methods and Results: Sixty isolates [47 (78.3%) multidrug-resistant (MDR)], which were identified as M. tuberculosis complex and phenotypically resistant to rifampicin by both BACTEC mycobacteria growth indicator tube (MGIT) 960 and 460 systems were analysed by a commercial line probe assay (INNO-LiPA Rif TB). The concordance of LiPA with the in vitro susceptibility test was found as 98.3%. Among the isolates, S531L (R5 pattern; 46.7%) and L511P/R, S512T, Q513L/K (Delta S1 pattern; 11.7%) were the most frequent mutation patterns. As compared with the BACTEC systems and conventional techniques for cultivation, identification and in vitro susceptibility testing, INNO-LiPA Rif TB after cultivation in BACTEC MGIT 960 system provided an average of 20 days early diagnosis of (RM)-M-r. tuberculosis isolates. Conclusions: Rapid molecular identification and characterization of (RM)-M-r. tuberculosis isolates after BACTEC MGIT 960 cultivation would be useful for faster diagnosis, infection control and planning of accurate treatment in MDR-TB patients. Significance and Impact of the Study: Patients with MDR-TB need a specified treatment and efficient follow-up strategies. Rapid and practical methodologies to diagnose and follow these patients should be applied in routine use.
  • No Thumbnail Available
    Item
    Multicenter evaluation of crystal violet decolorization assay (CVDA) for rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis
    Coban, AY; Akbal, AU; Bicmen, C; Albay, A; Sig, AK; Uzun, M; Selale, DS; Ozkutuk, N; Surucuoglu, S; Albayrak, N; Ucarman, N; Ozkutuk, A; Esen, N; Ceyhan, I; Ozyurt, M; Bektore, B; Aslan, G; Delialioglu, N; Alp, A
    The aim of this multicenter study was to evaluate the performance of the crystal violet decolorization assay (CVDA) for detection of multidrug resistant tuberculosis (MDR-TB). This study was performed in 11 centers in two phases. A total of 156 isolates were tested for INH and RIF resistance. In the phase I, 106 clinical isolates were tested in the Center 1-7. In the phase 2, 156 clinical isolates were tested in the center 1-6, center 8-11. Eighty six of 156 tested isolates were the same in phase I. Agreements were 96.2-96.8% for INH and 98.1-98.7% for RIF in the phase I-II, respectively. Mean time to obtain the results in the phase I was 14.3 +/- 5.4 days. In the phase II, mean time to obtain the results was 11.6 +/- 3.5 days. Test results were obtained within 14days for 62.3% (66/106) of isolates in the phase I and 81.4% (127/156) of isolates in the phase II. In conclusion, CVDA is rapid, reliable, inexpensive, and easy to perform for rapid detection of MDR-TB isolates. In addition, it could be adapted for drug susceptibility testing with all drugs both in developed and developing countries.
  • No Thumbnail Available
    Item
    A new colorimetric method for rapid detection of ethambutol and streptomycin resistance in Mycobacterium tuberculosis: crystal violet decolorization assay (CVDA)
    Coban, AY; Akbal, AU; Ceyhan, I; Uzun, M; Selale, DS; Aslan, G; Delialioglu, N; Ozyurt, M; Bektore, B; Bicmen, C; Aslanturk, A; Ucarman, N; Albay, A; Sig, AK; Ozkutuk, N; Surucuoglu, S
    Streptomycin (STR) and ethambutol (EMB) are important drugs used for the treatment of tuberculosis. There is a need for fast, reliable and inexpensive methods for detecting resistance to these drugs. The aim of this study was to evaluate the performance of the crystal violet decolorization assay (CVDA) for the detection of STR and EMB resistance that is important drugs in tuberculosis treatment. In this study, drug susceptibility testing was performed on 140 Mycobacterium tuberculosis isolates provided from nine centers. Three tubes were used for each isolate. One of the tubes had a concentration of 2mg/L STR and the other 5mg/L EMB. The third was drug-free control tube. Sensitivity, specificity, positive predictive value (PPD), negative predictive value (NPD) and agreement for STR were found to be 81.8%, 94.6%, 87.8%, 91.5% and 90.57%, respectively. For EMB, sensitivity, specificity, PPD, NPD, and agreement were found to be 76%, 98.23%, 90.47%, 94.87% and 94.2%, respectively. The results were obtained in 11.3 +/- 2.7days (8-21days). CVDA is rapid, reliable, inexpensive, and easy to perform for rapid detection of STR and EMB resistance, and it could be adapted for drug susceptibility testing.
  • No Thumbnail Available
    Item
    Multicenter evaluation of AYC.2.2 agar for the isolation of mycobacteria from clinical samples
    Coban, AY; Ceyhan, I; Uzun, M; Genc, GE; Bicmen, C; Ozkutuk, N; Surucuoglu, S; Yanar, O; Aslan, G; Kurnaz, N; Cayci, YT
    Purpose: The aim of this multicenter study is to evaluate AYC.2.2 agar for the isolation of mycobacteria from clinical samples. Methods: Totally 5559 media were tested in 7 centers. AYC.2.2 agar media for the study were prepared by C1 and sent to other centers under appropriate conditions. Other media except AYC.2.2 agar were purchased commercially. The media were subjected to routine laboratory operations in the center where they were sent. After the samples received for routine processing (in all centers, samples were processed with the same method (NALC-NaOH)), they were cultivated on routine media and AYC.2.2 agar afterward. Results: C1: Average growth time was determined as 12.74 +/- 3.74 days with MGIT 960 system; 24.42 +/- 4.75 days with LJ and 24.37 +/- 4.96 days with AYC.2.2 agar. C2: Average growth time was determined as 18.25 +/- 9.32 days with TK-Medium, 28.73 +/- 7.44 days with LJ, and 31.72 +/- 6.35 days with AYC.2.2 agar. C3: Average growth time was determined as 20.48 +/- 7.24 days with Ogawa medium, 20.74 +/- 7.12 days with LJ, and 20.26 +/- 7.43 days with AYC.2.2 agar. C4: Average growth time was determined as 15.27 +/- 6.37 days with MGIT 960 system, 22.14 +/- 9.1 days with LJ, and 22 +/- 8.45 days with AYC.2.2 agar. C5: Average growth time was determined as 13 +/- 4.24 days with MGIT 960 system, 32.16 +/- 6.23 days with LJ, and 33 +/- 5.73 days with AYC.2.2 agar. C6: Average growth time was determined as 9 +/- 3.11 days with MGIT 960 system, 18.68 +/- 5.32 days with LJ, and 18.34 +/- 4.63 days AYC.2.2 agar. C7: Average growth time was determined as 14.74 +/- 7.65 with MGIT 960 system, 26.01 +/- 8.21 days with LJ, and 26.24 +/- 7.88 days with AYC.2.2 agar. Conclusions: In conclusion, similar results were obtained with LJ and Ogawa media and AYC.2.2 agar. Furthermore, more studies should be conducted for isolation of M. tuberculosis and performing antibiotic susceptibility tests using AYC.2.2 agar before it can be used as a routine media in the laboratories.